TGTX

TG Therapeutics, Inc.

13.36 USD
+0.04 (+0.30%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

TG Therapeutics, Inc. stock is down -16.4% since 30 days ago. The next earnings date is Feb 28, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 66.67% of the previous 11 February’s closed higher than January. In the last 10 Unusual Options Trades, there were 2 PUTs, 8 CALLs. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
20 Feb 20:18 17 May, 2024 15.00 PUT 85 708
21 Feb 15:38 17 Jan, 2025 30.00 CALL 230 3573
21 Feb 15:47 17 Jan, 2025 5.00 CALL 154 7476
21 Feb 20:05 01 Mar, 2024 12.50 CALL 230 0
22 Feb 19:44 19 Apr, 2024 16.00 CALL 235 13
22 Feb 20:01 17 May, 2024 16.00 CALL 228 846
23 Feb 14:32 16 Aug, 2024 15.00 CALL 100 119
23 Feb 16:02 19 Apr, 2024 13.00 PUT 200 1
23 Feb 18:58 17 Jan, 2025 10.00 CALL 50 7413
23 Feb 19:00 17 Jan, 2025 10.00 CALL 48 7413

About TG Therapeutics, Inc.

TG Therapeutics, Inc. focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors. TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor.